Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nevro Corp (NVRO)
NYSE:NVRO
Holding NVRO?
Track your performance easily
NVRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.38 - $22.64
Previous Close$5.56
Volume925.97K
Average Volume (3M)611.65K
Market Cap
$199.46M
Enterprise Value$168.06M
Total Cash (Recent Filing)$273.69M
Total Debt (Recent Filing)$242.29M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 11, 2024EPS Estimate
-$0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding37,283,164
10 Day Avg. Volume515,903
30 Day Avg. Volume611,650
Standard Deviation0.15
R-Squared0.11
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.79
Price to Sales (P/S)0.49
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.39
Enterprise Value/Gross Profit0.58
Enterprise Value/Ebitda-9.23
Forecast
1Y Price Target
$6.00Price Target Upside3.81% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering8
Nevro Corp News
PremiumThe Fly
Nevro rises 17.1%
PremiumThe Fly
Nevro rises 9.8%Bulls Say, Bears Say
Bulls Say
Market ExpansionIntroducing SI Joint and other products could strengthen Nevro's contracting capabilities with larger health systems, diversifying its offerings beyond a single product focus.
Product InnovationNevro plans to launch a product enhancement for its iQ platform, called HFX AdaptiveAI, which will leverage data from 100,000 patients to provide advanced solutions for pain management.
Strategic ReviewNevro is actively exploring a range of strategic options, including potential partnerships, mergers, or a sale, which could enhance the company's growth and maximize shareholder value.
Bears Say
Financial PerformanceNevro missed Q2 revenue and lowered its 2024 revenue guidance, reflecting challenges in achieving profitability without growth.
Market CompetitionNevro's results were impacted by competitive pressures from recently launched products from large competitors and continued softness in the US spinal cord stimulation market.
Revenue GrowthNevro's 2H revenue growth to decelerate to around -10 from -4% in Q2, driven by trends in trials as physicians evaluate new competitive systems.
---
Ownership Overview
5.25% Insiders
21.96% Mutual Funds
2.52% Other Institutional Investors
58.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVRO FAQ
What was Nevro Corp’s price range in the past 12 months?
Nevro Corp lowest stock price was $4.38 and its highest was $22.64 in the past 12 months.
What is Nevro Corp’s market cap?
Currently, no data Available
When is Nevro Corp’s upcoming earnings report date?
Nevro Corp’s upcoming earnings report date is Nov 11, 2024 which is tomorrow.
How were Nevro Corp’s earnings last quarter?
Nevro Corp released its earnings results on Aug 06, 2024. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.697 by $0.167.
Is Nevro Corp overvalued?
According to Wall Street analysts Nevro Corp’s price is currently Undervalued.
Does Nevro Corp pay dividends?
Nevro Corp does not currently pay dividends.
What is Nevro Corp’s EPS estimate?
Nevro Corp’s EPS estimate is -$0.82.
How many shares outstanding does Nevro Corp have?
Nevro Corp has 37,283,165 shares outstanding.
What happened to Nevro Corp’s price movement after its last earnings report?
Nevro Corp reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.697. Following the earnings report the stock price went down -44.419%.
Which hedge fund is a major shareholder of Nevro Corp?
Among the largest hedge funds holding Nevro Corp’s share is Engaged Capital LLC. It holds Nevro Corp’s shares valued at 16M.
---
Nevro Corp Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$6.00 (3.81% Upside)
$6.00 (3.81% Upside)
Blogger Sentiment
Bullish
NVRO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 669.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.40%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
5.94%
Trailing 12-Months
Company Description
Nevro Corp
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
---
NVRO Company Deck
---
NVRO Earnings Call
Q2 2024
0:00 / 0:00
---
NVRO Stock 12 Month Forecast
Average Price Target
$6.00
▲(3.81% Upside)
Technical Analysis
Best Analysts Covering NVRO
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+28.62%
assigned a sell rating 3 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +28.62% per trade.
---